A Trial to Investigate Scar Improvement Efficacy of RN1001 (Avotermin) After Head and Neck Naevi Excision
Status:
Unknown status
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This trial will investigate whether four doses of RN1001 (20ng, 50ng, 100ng and 200ng) are
efficacious in preventing or reducing the resultant scar, as compared to placebo, when
applied intradermally to wound margins following excision of benign naevi situated on the
head and neck.